Try a new search

Format these results:

Searched for:

person:anf202

in-biosketch:true

Total Results:

84


Prominent dyspigmentation in a patient with dermatomyositis and TIF1-γ autoantibodies [Case Report]

Gutierrez, Daniel; Svigos, Katerina; Femia, Alisa; Brinster, Nooshin K; Lo Sicco, Kristen
PMCID:8958465
PMID: 35355654
ISSN: 2352-5126
CID: 5219942

Clinical Characteristics, Disease Course, and Outcomes of Patients With Acute Generalized Exanthematous Pustulosis in the US

Creadore, Andrew; Desai, Sheena; Alloo, Allireza; Dewan, Anna K; Bakhtiar, Mina; Cruz-Diaz, Carla; Femia, Alisa; Fox, Lindy; Katz, Kimberly L; Micheletti, Robert; Nelson, Caroline A; Ortega-Loayza, Alex G; Patrinely, J Randall; Plovanich, Molly; Rosenbach, Misha; Shaigany, Sheila; Shields, Bridget E; Saleh, Jamal Z; Sharif-Sidi, Zakariyah; Shinkai, Kanade; Smith, Jacob; Su, Chang; Wanat, Karolyn A; Wieser, Jill K; Wright, Shari; Noe, Megan H; Mostaghimi, Arash
Importance/UNASSIGNED:Acute generalized exanthematous pustulosis (AGEP) is a rare, severe cutaneous adverse reaction associated with systemic complications. Currently available data are largely limited to small retrospective case series. Objective/UNASSIGNED:To describe the clinical characteristics, disease course, and outcomes of a heterogeneous group of patients with AGEP across the US. Design, Setting, and Participants/UNASSIGNED:A retrospective review of a case series of patients was conducted from January 1, 2000, through July 31, 2020. All 340 included cases throughout 10 academic health systems in the US were scored retrospectively using the EuroSCAR scoring system, and patients with a score corresponding to probable or definite AGEP and aged 18 years or older were included. Main Outcomes and Measures/UNASSIGNED:Patient demographic characteristics, clinical course, suspected causative agent, treatment, and short- and long-term outcomes. Results/UNASSIGNED:Most of the 340 included patients were women (214 [62.9%]), White (206 [60.6%]), and non-Hispanic (239 [70.3%]); mean (SD) age was 57.8 (17.4) years. A total of 154 of 310 patients (49.7%) had a temperature greater than or equal to 38.0 °C that lasted for a median of 2 (IQR, 1-4) days. Of 309 patients, 263 (85.1%) developed absolute neutrophilia and 161 patients (52.1%) developed either absolute or relative eosinophilia. Suspected causes of AGEP were medications (291 [85.6%]), intravenous contrast agents (7 [2.1%]), infection (3 [0.9%]), or unknown (39 [11.5%]). In 151 cases in which a single medication was identified, 63 (41.7%) were β-lactam antimicrobials, 51 (33.8%) were non-β-lactam antimicrobials, 9 (6.0%) were anticonvulsants, and 5 (3.3%) were calcium channel blockers. The median time from medication initiation to AGEP start date was 3 (IQR, 1-9) days. Twenty-five of 298 patients (8.4%) had an acute elevation of aspartate aminotransferase and alanine aminotransferase levels, with a peak at 6 (IQR, 3-9) days. Twenty-five of 319 patients (7.8%) experienced acute kidney insufficiency, with the median time to peak creatinine level being 4 (IQR, 2-5) days after the AGEP start date. Treatments included topical corticosteroids (277 [81.5%], either alone or in combination), systemic corticosteroids (109 [32.1%]), cyclosporine (10 [2.9%]), or supportive care only (36 [10.6%]). All-cause mortality within 30 days was 3.5% (n = 12), none of which was suspected to be due to AGEP. Conclusions and Relevance/UNASSIGNED:This retrospective case series evaluation of 340 patients, the largest known study cohort to date, suggests that AGEP onset is acute, is usually triggered by recent exposure to an antimicrobial, may be associated with liver or kidney complications in a minority of patients, and that discontinuation of the triggering treatment may lead to improvement or resolution.
PMID: 34985493
ISSN: 2168-6084
CID: 5107142

Evaluation of a Case Series of Patients With Generalized Pustular Psoriasis in the United States

Noe, Megan H; Wan, Marilyn T; Mostaghimi, Arash; Gelfand, Joel M; Agnihothri, Ritesh; Armstrong, April W; Bhutani, Tina; Bridges, Alina; Brownstone, Nicholas; Butt, Melissa; Duffin, Kristina P Callis; Carr, Christian; Creadore, Andrew; DeNiro, Katherine L; Desai, Sheena; Dominguez, Arturo R; Duffy, Emily K; Fairley, Janet A; Femia, Alisa; Gudjonsson, Johann E; Kaffenberger, Jessica A; Katz, Kimberly L; Le, Stephanie T; Martinez, Edgar; Maverakis, Emanual; Myers, Bridget; Naik, Haley B; Nelson, Caroline A; Ortega-Loayza, Alex G; Plovanich, Molly E; Rangel, Lauren K; Ravi, Vignesh; Reddy, Vidhatha D; Saleh, Jamal Z; Kirby, Joslyn S; Sandhu, Jeena K; Shakshouk, Hadir; Shields, Bridget E; Sharif-Sidi, Zakariyah; Smith, Jacob; Steahr, Amanda; Toussi, Atrin; Wanat, Karolyn A; Wang, Bo; Wei, Brian M; Weinhammer, Annika; Worswick, Scott D; Yang, Alexander
Importance/UNASSIGNED:Generalized pustular psoriasis (GPP) is a chronic, orphan disease with limited epidemiological data. Objective/UNASSIGNED:To describe the clinical characteristics, treatments, longitudinal disease course, and disease-specific health care utilization among patients with GPP across the United States. Design, Setting, and Participants/UNASSIGNED:A retrospective longitudinal case series involving 95 adults who met the European Rare and Severe Psoriasis Expert Network consensus definition for GPP and were treated at 20 US academic dermatology practices between January 1, 2007, and December 31, 2018. Main Outcomes and Measures/UNASSIGNED:The primary outcome is to describe the patient characteristics, associated medical comorbidities, treatment patterns complications, and GPP-specific health care utilization. Results/UNASSIGNED:Sixty-seven of 95 patients (70.5%) were women (mean age, 50.3 years [SD, 16.1 years]). In the initial encounter, 35 patients (36.8%) were hospitalized and 64 (67.4%) were treated with systemic therapies. In total, more than 20 different systemic therapies were tried. During the follow-up period, 19 patients (35.8%) reported hospitalizations at a median rate of 0.5 hospitalizations per year (IQR, 0.4-1.6). Women had a decreased risk of an emergency department or hospital encounter (odds ratio, 0.19; 95% CI, 0.04-0.83). Conclusions and Relevance/UNASSIGNED:Generalized pustular psoriasis is a rare, chronic disease without standard treatment and is associated with continued health care utilization over time.
PMCID:8655659
PMID: 34878491
ISSN: 2168-6084
CID: 5110252

Evaluation of a Case Series of Patients With Palmoplantar Pustulosis in the United States

Noe, Megan H; Wan, Marilyn T; Mostaghimi, Arash; Gelfand, Joel M; Agnihothri, Ritesh; Armstrong, April W; Bhutani, Tina; Bridges, Alina; Brownstone, Nicholas; Butt, Melissa; Duffin, Kristina P Callis; Carr, Christian; Creadore, Andrew; DeNiro, Katherine L; Desai, Sheena; Dominguez, Arturo R; Duffy, Emily K; Fairley, Janet A; Femia, Alisa; Gudjonsson, Johann E; Kaffenberger, Jessica A; Katz, Kimberly L; Kirby, Joslyn S; Le, Stephanie T; Martinez, Edgar; Maverakis, Emanual; Myers, Bridget; Naik, Haley B; Nelson, Caroline A; Ortega-Loayza, Alex G; Plovanich, Molly E; Rangel, Lauren K; Ravi, Vignesh; Reddy, Vidhatha D; Saleh, Jamal Z; Sandhu, Jeena K; Shakshouk, Hadir; Shields, Bridget E; Sharif-Sidi, Zakariyah; Smith, Jacob; Steahr, Amanda; Toussi, Atrin; Wanat, Karolyn A; Wang, Bo; Wei, Brian M; Weinhammer, Annika; Worswick, Scott D; Yang, Alexander
Importance/UNASSIGNED:Palmoplantar pustulosis (PPP) is a is a chronic, orphan disease with limited epidemiological data. Objective/UNASSIGNED:To describe the clinical characteristics, treatments, longitudinal disease course, and health care utilization in adults with PPP across the US. Design, Setting, and Participants/UNASSIGNED:This retrospective, longitudinal case series from 20 academic dermatology practices in the US included a consecutive sample of 197 adults who met the European Rare and Severe Psoriasis Expert Network consensus definition for PPP between January 1, 2007, and December 31, 2018. Data analysis was performed June 2020 to December 2020. Main Outcomes and Measures/UNASSIGNED:The primary outcome was to describe the patient characteristics, associated medical comorbidities, treatment patterns, complications, and PPP-specific health care utilization. Results/UNASSIGNED:Of 197 patients, 145 (73.6%) were female, and the mean (SD) age at presentation was 53.0 (12.6) years, with a mean (SD) follow-up time of 22.1 (28.0) months. On initial presentation, 95 (48.2%) patients reported skin pain, and 39 (19.8%) reported difficulty using hands and/or feet. Seventy patients (35.5%) were treated with systemic treatments, and use of more than 20 different systemic therapies was reported. In patients with at least 6 months of follow-up (n = 128), a median (IQR) of 3.7 (4-10) dermatology visits per year were reported; 24 (18.8%) patients had 5 or more visits during the study period. Conclusions and Relevance/UNASSIGNED:In this case series, PPP was associated with persistent symptoms, continued health care utilization, and a lack of consensus regarding effective treatments, emphasizing the unmet medical need in this population. Additional research is necessary to understand treatment response in these patients.
PMCID:8655660
PMID: 34878495
ISSN: 2168-6084
CID: 5110272

Profound leukemia cutis in a patient with relapsed T-cell acute lymphoblastic leukemia [Case Report]

Nohria, Ambika; Criscito, Maressa C; Weston, Gillian K; Kim, Randie H; Lo Sicco, Kristen I; Femia, Alisa N; Hejazi, Emily Z; Milam, Emily C
PMCID:8593518
PMID: 34815993
ISSN: 2352-5126
CID: 5063622

Diagnostic work-up and treatment in patients with pyoderma gangrenosum: retrospective analysis of US insurance claims-based data

Shaigany, Sheila; Wong, Priscilla W; Caplan, Avrom; Kim, Randie H; Femia, Alisa
Pyoderma gangrenosum (PG) is a rare, and often challenging to diagnose, inflammatory disorder with relatively high rates of morbidity and mortality. Central to the diagnosis of PG is histologic evaluation and exclusion of other entities. Large-scale studies investigating the proportion of patients receiving a thorough diagnostic work-up, as well as prevalence studies regarding comorbidities and systemic treatment in PG using claims-based data, are sparse. Our objective was to identify patients diagnosed with PG and describe the diagnostic work-up and prevalence of common comorbidities and therapies in this population using claims-based data in a retrospective cohort study. In order to better understand practices of diagnostic work-up, we captured rates of skin biopsy, tissue culture, and/or surgical debridement prior to initial diagnosis. We also identified the prevalence of PG-associated comorbidities and initial immunosuppressive therapy given for PG. Of the 565 patients diagnosed with PG, 9.4% underwent skin biopsy, 8% tissue culture, and 1.4% both skin biopsy AND tissue culture prior to diagnosis. Inflammatory bowel disease was the most prevalent comorbidity (16.3%). The most common treatment administered was systemic corticosteroids (17%). Although practice guidelines explicitly delineate histology and exclusion of infection as important diagnostic criteria, only a minority of patients in this study underwent skin biopsy and/or tissue culture prior to receiving a diagnosis of PG, suggesting that patients may receive a diagnosis of PG without having tissue evaluation. Such discordance between practice guidelines and "real-world" practice inevitably increases the risk for misdiagnosis of PG and misdirected treatment with immunosuppressants for presumptive PG in cases of PG mimickers. Moreover, comorbidities associated with PG may occur, or be identified in, a lower proportion of patients as compared with what is reported in the existing literature. Study limitations include a population restricted to < 65 years with commercial insurance and the reliance upon ICD diagnostic coding to capture the population.
PMID: 34714405
ISSN: 1432-069x
CID: 5042872

Disseminated Cryptococcosis [Case Report]

Akintilo, Lisa; Femia, Alisa
PMID: 34706174
ISSN: 1533-4406
CID: 5042552

Evaluating the Contributions of Dermatologists in the Management of Systemic Sclerosis: A Retrospective Analysis [Letter]

Rangel, Lauren K; Adotama, Prince; Shah, Payal; Lo Sicco, Kristen; Femia, Alisa
Systemic Sclerosis (SSc) is an autoimmune condition characterized by cutaneous sclerosis and the potential for internal organ involvement.1 Given the multisystem nature of SSc, multiple disciplines are often involved in its management. However, while the skin is affected in more than 90% of patients,2 dermatologists are variably involved in the management of SSc, potentially first evaluating patients only late in the disease course, or at times not at all.
PMID: 33866612
ISSN: 1468-3083
CID: 4878032

A narrative review of therapies for scalp dermatomyositis

Kolla, Avani M; Liu, Lynn; Shaw, Katharina; Shapiro, Jerry; Femia, Alisa; Lo Sicco, Kristen
Cutaneous involvement of the scalp is a common manifestation of dermatomyositis (DM), occurring in up to 82% of adults with DM. Scalp DM predominantly affects women and is characterized by dermatitis, alopecia, pruritus, and/or burning. While cutaneous DM negatively impacts quality-of-life, scalp symptoms in particular are often severe, debilitating, and recalcitrant to standard DM therapies. Currently, there is a paucity of guidelines to inform management of scalp symptoms in patients with cutaneous DM. In this narrative review, we summarize the treatments utilized to manage scalp DM and highlight potential areas for future research. We identified eight studies that reported on 27 treatments focused on cutaneous DM and described outcomes on scalp symptoms. A majority of the treatments were standard therapies for cutaneous DM and resulted in no or minimal improvement in scalp symptoms. Five therapies did result in complete resolution of scalp symptoms and were recommended as potential areas of future research. These included low-dose naltrexone and platelet-rich plasma, as well as two frequent and one less common therapy for cutaneous DM respectively: intravenous immunoglobulin, rituximab, and apremilast. Though the literature was not systematically assessed in this review, these findings illustrate not only that strategies for refractory scalp DM are lacking, but also that those demonstrating potential efficacy are limited by low levels of evidence. Additional studies, especially randomized controlled trials, are needed to better inform management of scalp DM.
PMID: 34549494
ISSN: 1529-8019
CID: 5067342

Response to "Patient preference for cellulitis treatment: at-home care is preferred to hospital-based treatment" [Letter]

Shaw, Katharina S; Karagounis, Theodora K; Yin, Lu; Gibbon, Grace; Betensky, Rebecca A; Lo Sicco, Kristen I; Femia, Alisa N
PMCID:7413198
PMID: 32777319
ISSN: 1097-6787
CID: 4556092